

APTUS PHARMA LIMITED

Date: 26.02.2026

To,

The BSE Ltd

Phiroze Jeejeebhoy Tower,

Dalal Street,

Mumbai – 400001

SECURITY CODE: 544529

SCRIPT SYMBOL: APPL

Dear Sir,

Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015: Business Expansion

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby inform that Aptus Pharma Limited (“the Company”), further to its recent foray into the OTC and Uro Care segment, has initiated expansion into the **Life-Saving Injectables and ICU Care product category**.

The proposed portfolio will comprise products intended for the management of severe infections, sepsis, and other critical care conditions, primarily administered in hospital and intensive care settings. This strategic expansion aligns with the Company’s objective of strengthening its presence across prescription, institutional, and retail healthcare segments.

The above expansion forms part of the Company’s growth strategy and is expected to enhance its product portfolio in high-acuity therapeutic segments.

This is for the information of the exchange and stakeholders. Kindly take the same on record.

Yours faithfully,

For Aptus Pharma Limited

Tejash Hathi
Managing Director
DIN: 03151221

Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM